TLDR AbbVie closes $10.9B Apogee deal and expands its immunology treatment pipeline. ABBV stock rises as Apogee adds key programs targeting dermatitis and asthma. Zumilokibart becomes a major new asset in AbbVie’s expanding immunology pipeline. AbbVie expects near-term EPS diluti...